Clinical Research Article

Vitamin D Status in Hospitalized Patients with SARS-CoV-2 Infection

José L. Hernández,1,10 Daniel Nan,1,10 Marta Fernandez-Ayala,1 Mayte García-Unzueta,2 Miguel A. Hernández-Hernández,3 Marcos López-Hoyos,4 Pedro Muñoz-Cacho,5 José M. Olmos,1,10 Manuel Gutiérrez-Cuadra,6 Juan J. Ruiz-Cubillán,7 Javier Crespo,8,10 and Víctor M. Martínez-Taboada9,10

1Department of Internal Medicine, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain; 2Division of Clinical Biochemistry, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain; 3Division of Intensive Care, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain; 4Division of Immunology, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain; 5Gerencia de Atención Primaria, Servicio Cántabro de Salud, Santander, Spain; 6Division of Infectious Diseases, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain; 7Division of Pneumology, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain; 8Division of Gastroenterology, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain; 9Division of Rheumatology, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain; and 10University of Cantabria, Santander, Spain

ORCiD number: 0000-0002-6585-8847 (J. L. Hernández).

Abbreviations: 25OHD, 25-hydroxyvitamin D; ARDS, acute respiratory distress syndrome; CV, coefficient of variation; GFR, glomerular filtration rate; ICU, intensive care unit; IL, interleukin; IMID, immune-mediated inflammatory disease; IQR, interquartile range; PTH, parathyroid hormone; RAS, renin–angiotensin system; SD, standard deviation.

Received: 3 June 2020; Accepted: 9 October 2020; First Published Online: 27 October 2020; Corrected and Typeset: 7 November 2020.

Abstract

Background: The role of vitamin D status in COVID-19 patients is a matter of debate.

Objectives: To assess serum 25-hydroxyvitamin D (25OHD) levels in hospitalized patients with COVID-19 and to analyze the possible influence of vitamin D status on disease severity.

Methods: Retrospective case–control study of 216 COVID-19 patients and 197 population-based controls. Serum 25OHD levels were measured in both groups. The association of serum 25OHD levels with COVID-19 severity (admission to the intensive care unit, requirements for mechanical ventilation, or mortality) was also evaluated.

Results: Of the 216 patients, 19 were on vitamin D supplements and were analyzed separately. In COVID-19 patients, mean ± standard deviation 25OHD levels were 13.8 ± 7.2 ng/mL, compared with 20.9 ± 7.4 ng/mL in controls (P < .0001). 25OHD values were lower in men than in women. Vitamin D deficiency was found in 82.2% of COVID-19 cases and 47.2% of population-based controls (P < .0001). 25OHD inversely correlates with serum ferritin (P = .013) and D-dimer levels (P = .027). Vitamin D-deficient COVID-19 patients had a greater prevalence of hypertension and cardiovascular diseases, raised
serum ferritin and troponin levels, as well as a longer length of hospital stay than those with serum 25OHD levels ≥20 ng/mL. No causal relationship was found between vitamin D deficiency and COVID-19 severity as a combined endpoint or as its separate components. **Conclusions:** 25OHD levels are lower in hospitalized COVID-19 patients than in population-based controls and these patients had a higher prevalence of deficiency. We did not find any relationship between vitamin D concentrations or vitamin deficiency and the severity of the disease.

**Freeform/Key Words:** 25OHD, PTH, SARS-CoV-2 infection, COVID-19

There are several lines of evidence that might support a role for vitamin D status in SARS-CoV-2 infection. Firstly, vitamin D deficiency is a common condition all around the world, and serum 25-hydroxyvitamin D (25OHD) levels follow a well-known seasonal and geographical pattern. Spain, located in temperate zones of the Northern Hemisphere, but with a higher prevalence of vitamin D deficiency (1), has reached very high rates of SARS-CoV-2 infection and lethality (2). Secondly, vitamin D is a steroid hormone involved in the modulation of the innate and acquired immune system and also in the production of antimicrobial peptides, such as cathelicidin and human β-defensin-2, as well as in the expression of genes involved in the intracellular destruction of pathogens (3-5). Thirdly, low serum 25OHD levels are frequently found in elderly individuals or in those with chronic conditions, such as hypertension, diabetes, cancer, or cardiovascular diseases, which have also been reported as poor prognostic factors for COVID-19 (6-11). Finally, the downregulation of ACE2 by SARS-CoV-2 leads to a dysregulation of the renin–angiotensin system (RAS), which contributes to the “cytokine storm” that precedes the acute respiratory distress syndrome (ARDS) characteristic of the severe form of COVID-19. In this sense, vitamin D can inhibit proinflammatory cytokine production in human monocytes/macrophages (12), and chronic vitamin D deficiency may induce RAS activation, leading to the production of fibrotic factors and, therefore, lung damage (13).

Taking into account the above considerations, we aimed to assess the serum 25OHD levels in hospitalized patients with COVID-19 compared with population-based controls. The possible association between serum 25OHD concentrations and COVID-19 severity and mortality was also analyzed.

**Patients and Methods**

**Study design and participants**

The study consists of 2 parts. Firstly, we have designed a retrospective case–control study including 216 patients aged ≥18 years with confirmed COVID-19 admitted to the University Hospital Marqués de Valdecilla in Santander, northern Spain, from March 10 to March 31, 2020, and 197 sex-matched population-based controls recruited from the Camargo Cohort (14, 15) during their last follow-up visit in January to March of the past year. From the present study, we have excluded patients or controls with malabsorption disorders, liver cirrhosis, serum creatinine levels >1.9 mg/dL, or previous treatment with anticonvulsants. Nineteen COVID-19 patients on oral vitamin D supplements for more than 3 months at admission were analyzed as a separate group, and controls who receive these supplements were also excluded from the study. Secondly, we have assessed only the group of COVID-19 patients to evaluate the possible influence of vitamin D deficiency on the outcome of the disease. Participants from the Camargo Cohort gave their informed written consent and the study was approved by the Cantabria Clinical Research Ethics Committee (internal code 2016.003). The present study was approved by the Ethics Committee of Cantabria (internal code 2020.55). Serum samples from Covid-19 patients were provided by the IDIVAL Biobank samples collection (internal code 2020-126).

**Data collection**

Demographic, clinical, and outcome data of COVID-19 patients were gathered from hospital records, stored in a computerized database, and independently reviewed by 2 researchers. Missing data were not imputed. Smoking status was coded as current or nonsmoker. Immunosuppression included prolonged use (≥3 months) of corticoids (>10 mg/day of prednisone or equivalent) or immunomodulatory agents, and bone marrow or organ transplantation. Chest X-ray and/or computed tomography scans were performed in all COVID-19 patients. Concerning immunomodulatory therapy, patients were selected for tocilizumab according to our institutional protocol. Thus, tocilizumab was indicated if there was clinical worsening with PaO₂/FIO₂ ratio <300 and high serum acute-phase reactant levels when no contraindication for its use was present. The endpoint variable for COVID-19 severity has been defined as the
composite of admission to the intensive care unit (ICU), requirement for mechanical ventilation, or in-hospital mortality. Clinical outcomes were monitored up to May 20, 2020. Overall, the criteria for ICU admission were those of the guidelines by the American Thoracic Society and Infectious Diseases Society of America (16) and the critical care ethic recommendations for the SARS-CoV-2 pandemic by the Intensive Medicine Spanish Society (17). ARDS was the main cause of ICU admission and a case-by-case assessment was carried out by the medical COVID team, including intensivists.

Laboratory measurements
Qualitative detection of RNA from the SARS-CoV-2 was performed by using real-time polymerase chain reaction. Blood samples from the controls were obtained from an antecubital vein in the morning after a requested 12-hour overnight fast. The serum was divided into 0.5-mL aliquots and stored at –40°C. Routine biochemical parameters were measured by standard automated methods in a Technicon Dax autoanalyzer (Technicon Instruments, CO, USA). Human interleukin (IL)-6 was measured by enzyme-linked immunosorbent assay (Enzo Life Sciences, Inc. Farmingdale, NY) following the manufacturer instructions. The sensitivity for serum IL-6 levels was 0.057 pg/mL. Intra- and interassay precision was 4.38% and 9.6%, respectively. Serum 25OHD concentrations were determined in controls by a fully automated electrochemiluminescence system (Elecsys 2010, Roche Diagnostics, GmbH, Mannheim, Germany). The detection limit of serum 25OHD was 4 ng/mL. The intra-assay coefficient of variation (CV) was 5% and interassay was 7.5%. In COVID-19 patients, serum 25OHD levels were obtained at admission and assessed by automated competitive chemiluminescence assay (Liaison XL, DiaSorin Inc, Stillwater MN, USA). Our laboratory is DEQAS (Vitamin D External Quality Assessment Scheme) certified for this parameter. The detection limit of serum 25OHD was 4 ng/mL. The intra-assay and interassay CV were 2.58% and 7.83%, respectively. We have previously found a correlation between both techniques of 0.926 (P < .0001) with a random sample of 52 subjects from the Camargo Cohort.

Statistical analysis
Continuous variables were expressed as mean ± standard deviation (SD) or median and interquartile range and compared with the Student’s t-test or Mann–Whitney U test according to the distribution of data. Categorical variables were presented as numbers and percentages and compared using the chi-squared test or the Fisher exact test as appropriate. Spearman rho was used to assess the relationships between serum 25OHD levels and several clinical and laboratory parameters. Serum 25OHD levels were stratified into 4 categories: below 10 ng/mL, between 10 and 20 ng/mL, between 20 and 30 ng/mL, and above 30 ng/mL. Vitamin D deficiency was defined as serum 25OHD levels <20 ng/mL (50 nmol/L) following a recent position paper by the European Calcified Tissue Society Working Group (18). A multivariable general linear model was set up to compare serum 25OHD levels between COVID-19 patients and controls (Bonferroni test), adjusting for confounding variables. In the group of COVID-19 patients, univariable and multivariable binary logistic regression analyses were used to assess the association between vitamin D (as a continuous variable, or expressed as vitamin D deficiency or as quintiles) and the dependent variable of severity of the disease. A 2-sided P-value less than .05 was considered statistically significant in all the calculations. A post hoc power analysis with the present sample size and the obtained difference in serum 25OHD levels between cases and controls yields a power of 100% to detect this difference. In fact, a difference of 2.1 ng/mL between groups already yields a potency of 89.8%. Nevertheless, due to the sample size and the lower number of events (especially mortality) in COVID-19 patients with and without vitamin D deficiency, the post hoc power analysis for the severity endpoints was lower than 40%.

Results
We included 216 adult COVID-19 patients, of whom 19 were on vitamin D supplementation (11 patients were taking cholecalciferol, 25 000 IU/monthly in 10 cases, and 5600 IU/weekly in 1, and 8 patients were on calcifediol, 0.266 mg/monthly). The main demographic, epidemiological, and clinical characteristics of the 3 groups included in the study are summarized in Table 1. COVID-19 patients on vitamin D supplements were mainly women and had a greater prevalence of hypertension and immunosuppression than the other 2 groups analyzed. Population-based controls included more smokers and had a lower glomerular filtration rate and greater serum parathyormone levels than COVID-19 patients. Table 2 summarizes the demographic, clinical, and laboratory data of COVID-19 patients (excluding those on vitamin supplements) according to the presence of vitamin D deficiency (serum 25OHD levels <20 ng/mL). Vitamin D-deficient COVID-19 patients had a greater prevalence of hypertension and cardiovascular diseases, raised serum ferritin and troponin levels, as well as a longer length of hospital stay than those with serum 25OHD levels ≥20 ng/mL. The features of COVID-19 patients according to the active use of vitamin D supplements are shown in Table 3.
Patients on supplements had a significantly lower PaO2/FIO2 ratio <300 prevalence, lower serum ferritin levels, and received less frequently tocilizumab than COVID-19 patients who did not take vitamin D supplements. They also had an overall lower percentage of the combined severity endpoint and ICU admissions, as well as a shorter length of hospital stay, although these data did not reach statistical significance.

Furthermore, when we pooled together patients with 25OHD levels ≥20 ng/mL (both at basal levels and with vitamin D supplements) and compared with patients with vitamin D deficiency, those with higher levels had a slightly better outcome expressed as a lower PaO2/FIO2 ratio <300 (12.8% vs. 27.8%; \( P = .034 \)), lower requirements for tocilizumab (17% vs. 33.1%; \( P = .032 \)), less frequent radiological progression (14.9% vs. 30.2%; \( P = .037 \)), lower ICU admissions (12.8% vs. 26.6%; \( P = .048 \)), and also a shorter hospital stay (12.0 [8.0-17.0] vs. 8.0 [6.0-14.0] days; \( P = .002 \)). No difference was found regarding the composite severity endpoint (21.3% vs. 30.8%; \( P = .203 \)) nor mortality (12.9% vs. 9.8%; \( P = .590 \)).

In COVID-19 patients, mean ± SD 25OHD levels were 13.8 ± 7.2 ng/mL, compared with 20.9 ± 7.4 ng/mL in controls \( P < .0001 \). The distribution of serum 25OHD levels in hospitalized COVID-19 patients with or without vitamin D supplements and controls, grouped by gender, is shown in Fig. 1. Serum 25OHD values were lower in men than in women. Fig. 2 shows the percentage of COVID-19 cases (without vitamin D supplementation) and controls within the different intervals of serum 25OHD levels. Vitamin D deficiency was found in 82.2% of COVID-19 cases and 47.2% of population-based controls \( (P < .0001) \). 25OHD inversely and significantly correlated with serum ferritin and D-dimer, and there was a trend with C-reactive protein levels (Fig. 3). We did not find any statistical relationship between serum vitamin D and IL-6 levels in patients with COVID-19 (rho –0.032; \( P = .67 \)), although levels of this cytokine were lower, albeit nonsignificant, in patients with serum vitamin D levels ≥20 ng/mL and those on vitamin D supplements (Table 3).

In the multivariable general linear model, mean serum 25OHD levels were significantly lower in COVID-19 patients (excluding those on vitamin D supplements) than in population-based controls after adjusting for age, smoking, hypertension, diabetes mellitus, history of cardiovascular events, immunosuppression, body mass index, serum corrected calcium, glomerular filtration rate, and the month of vitamin D determination: 11.9 (95% CI 9.6-14.3) ng/mL versus 21.2 (95% CI 19.7-22.7) ng/mL \( (P < .0001) \).

In COVID-19 patients (once those on vitamin D supplements at admission had been excluded), no relationship was found between serum vitamin D levels (as a continuous variable or expressed as vitamin D deficiency or as quintiles), and the composite severity endpoint or its separate components, in crude or adjusted logistic regression models (combine severity endpoint: unadjusted OR 1.55, 95% CI 0.66-3.65; \( P = .315 \); adjusted OR 1.13, 95% CI 0.27-4.77; \( P = .865 \); for vitamin D deficiency).

### Table 1. Main baseline features of COVID-19 patients and controls

| Variable | COVID-19 | COVID-19_D | Controls | \( P^a \) | \( P^b \) | \( P^c \) |
|----------|----------|------------|----------|--------|--------|--------|
| N = 197  | N = 19   | N = 197    |          |        |        |        |
| Age (years), median (IQR) | 61.0 (47.5-70.0) | 60.0 (59.0-75.0) | 61.0 (56.0-66.0) | .082 | .153 | .182 |
| Sex (male), n (%) | 123 (62.4) | 7 (36.8) | 123 (62.4) | .030 | .999 | .030 |
| BMI (kg/m²), mean ± SD | 29.2 ± 4.7 | 30.9 ± 6.3 | 28.9 ± 4.0 | .134 | .557 | .035 |
| Current smoker, n (%) | 14 (7.1) | 2 (10.5) | 34 (17.3) | .638 | .002 | .747 |
| Hypertension, n (%) | 76 (38.6) | 12 (63.2) | 87 (44.2) | .037 | .260 | .113 |
| Diabetes, n (%) | 34 (17.3) | 0 (0.0) | 31 (15.7) | .049 | .684 | .083 |
| Cardiovascular disease, n (%) | 21 (10.7) | 3 (15.8) | 22 (11.2) | .451 | .872 | .468 |
| COPD, n (%) | 15 (7.6) | 2 (10.5) | 9 (4.6) | .650 | .206 | .250 |
| Active cancer, n (%) | 7 (3.6) | 0 (0.0) | 8 (4.1) | .999 | .792 | .999 |
| Immunosuppression, n (%) | 16 (8.1) | 6 (31.6) | 2 (1.0) | .006 | .001 | <.0001 |
| ACEI / ARA2 agents, n (%) | 58 (29.4) | 7 (36.8) | 47 (23.9) | .502 | .210 | .265 |
| GFR-MDRD-4 (mL/min/1.73 m²), median (IQR) | 92.2 (73.9-113.4) | 85.9 (69.9-104.9) | 71.9 (63.3-91.5) | .213 | <.0001 | .053 |
| C-reactive protein (mg/dl), median (IQR) | 5.60 (2.63-11.85) | 7.30 (2.90-15.10) | 8.7 (4.42-11.7) | .025 | <.0001 | <.0001 |
| Corrected calcium (mg/dL), median (IQR) | 8.5 (8.3-9.0) | 8.7 (8.4-9.0) | 9.1 (8.9-9.3) | .175 | <.0001 | <.0001 |
| 25OHD (ng/mL), mean ± SD | 13.8 ± 7.2 | 21.1 ± 5.9 | 20.9 ± 7.4 | <.0001 | <.0001 | .914 |
| PTH (pg/mL), median (IQR) | 42.6 (32.3-62.6) | 53.7 (28.8-67.4) | 51.6 (42.5-65.2) | .389 | <.0001 | .719 |

Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; ACEI, angiotensin-converting enzyme inhibitors; ARA2, angiotensin-receptor 2 antagonists; GFR, glomerular filtration rate; MDRD, modification of diet in renal disease; 25OHD, 25-hydroxyvitamin D; PTH, parathyroid hormone.

*COVID-19 group vs COVID19_D group.

*COVID-19 group vs Controls.

*COVID-19_D group vs Controls.
Table 2. Main characteristics of COVID-19 patients according to the presence of vitamin D deficiency

| Variable | 25OHD < 20 ng/mL | 25OHD ≥ 20 ng/mL | P  |
|----------|-----------------|-----------------|----|
| N = 162  | N = 35          |                 |    |
| **Baseline characteristics** |                  |                 |    |
| Age (years), median (IQR) | 62.0 (48.0-70.3) | 58.0 (45.0-69.0) | .292 |
| Sex (male), n (%) | 106 (65.4) | 17 (48.6) | .062 |
| BMI (kg/m²), mean ± SD | 29.0 ± 4.9 | 29.8 ± 4.1 | .428 |
| Current smoker, n (%) | 13 (8.0) | 1 (2.9) | .471 |
| Hypertension, n (%) | 68 (42.0) | 8 (22.9) | .035 |
| Diabetes, n (%) | 28 (17.3) | 6 (17.1) | .984 |
| Cardiovascular disease, n (%) | 21 (13.0) | 0 (0.0) | .029 |
| Active cancer, n (%) | 7 (4.3) | 0 (0.0) | .357 |
| Immunosuppression, n (%) | 11 (6.8) | 5 (14.3) | .169 |
| ACEI/ARA2 agents, n (%) | 52 (32.1) | 6 (17.1) | .078 |
| **Clinical and laboratory data** |                  |                 |    |
| Pneumonia, n (%) | 155 (95.7) | 33 (94.3) | .662 |
| Respiratory rate >22, n (%) | 36 (22.2) | 4 (11.4) | .150 |
| CURB-65 score, median (IQR) | 1 (1, 2) | 1 (1) | .229 |
| SBP < 100 mmHg, n (%) | 4 (2.5) | 1 (2.9) | .999 |
| PaO₂/FIO₂ ratio, median (IQR) | 444 (424-452) | 444 (436-452) | .168 |
| Lymphocytes (mm³), median (IQR) | 900 (600-1200) | 1100 (700-1250) | .255 |
| Neutrophils (mm³), median (IQR) | 3900 (2875-6125) | 3700 (2900-4600) | .207 |
| Neutrophil/Lymphocyte ratio, median (IQR) | 4.85 (3.00-7.52) | 3.63 (3.00-6.67) | .422 |
| Platelet count (x10⁹/L), median (IQR) | 167 (138-217) | 169 (143-211) | .833 |
| D-dimer (ng/mL), median (IQR) | 710.5 (469.0-1021.0) | 575.0 (434.0-693.0) | .057 |
| Ferritin (ng/mL), median (IQR) | 833.0 (330.8-1488.3) | 310.0 (137.3-764.0) | <.0001 |
| hs-Troponin I (ng/L), median (IQR) | 6.0 (3.0-12.0) | 3.0 (3.0-6.0) | .015 |
| C-reactive protein (mg/dL), median (IQR) | 6.10 (3.10-13.60) | 3.20 (2.30-8.70) | .064 |
| IL-6 (pg/mL), median (IQR) | 58.9 (19.1-124.0) | 45.6 (20.5-119.0) | .63 |
| GFR-MDRD-4 (mL/min/1.72 m²), median (IQR) | 91.4 (73.5-114.7) | 98.0 (82.4-113.1) | .323 |
| Corrected calcium (mg/dL), median (IQR) | 8.5 (8.3-9.0) | 8.7 (8.4-9.0) | .289 |
| 25OHD (ng/mL), mean ± SD | 11.2 ± 4.3 | 25.8 ± 5.6 | <.0001 |
| PTH (pg/mL), median (IQR) | 84.2 (32.3-64.8) | 35.6 (30.9-46.4) | .092 |
| **Therapeutic scheme** |                  |                 |    |
| Hydroxychloroquine, n (%) | 156 (96.3) | 35 (100) | .593 |
| Lopinavir/ritonavir, n (%) | 122 (75.3) | 31 (88.6) | .088 |
| Azithromycin, n (%) | 117 (72.2) | 30 (85.7) | .096 |
| Corticosteroids, n (%) | 40 (24.7) | 7 (20.0) | .555 |
| β-Interferon, n (%) | 37 (22.8) | 7 (20.0) | .715 |
| Tocilizumab, n (%) | 55 (34.0) | 8 (22.9) | .202 |
| Anakinra, n (%) | 12 (7.4) | 1 (2.9) | .471 |
| Noninvasive ventilation, n (%) | 12 (7.4) | 1 (2.9) | .471 |
| **Outcome** |                  |                 |    |
| ICU admission, n (%) | 44 (27.2) | 6 (17.1) | .217 |
| Mechanical ventilation*, n (%) | 37 (84.1) | 6 (100) | .576 |
| Radiological worsening, n (%) | 50 (30.9) | 6 (17.1) | .103 |
| Secondary infection, n (%) | 38 (23.5) | 6 (17.1) | .416 |
| Thrombotic events*, n (%) | 10 (6.2) | 0 (0.0) | .214 |
| Death, n (%) | 16 (10.2) | 4 (11.4) | .765 |
| Composite severity endpoint, n (%) | 111 (68.5) | 27 (77.1) | .312 |
| Length of stay (days), median (IQR) | 12.0 (8.0-17.0) | 8.0 (6.0-14.0) | .013 |

Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; ACEI, angiotensin-converting enzyme inhibitors; ARA2, angiotensin-receptor 2 antagonists; hs, high-sensitivity; GFR, glomerular filtration rate; MDRD, modification of diet in renal disease; 25OHD, 25-hydroxyvitamin D; PTH, parathyroid hormone.

*Refers only to the number of patients admitted to ICU.

†Included pulmonary embolism, deep venous thrombosis, acute coronary syndrome, and cerebrovascular disease.
Discussion

We have found that serum 25OHD levels are significantly lower in hospitalized COVID-19 patients than in population-based controls of similar age and sex, and that these differences remain significant even after adjusting for the main confounding factors. These levels were especially lower in the group of men with COVID-19. Despite the high frequency of vitamin D deficiency in patients hospitalized for COVID-19, we did not find an association between circulating levels of 25OHD and the severity of SARS-CoV-2 infection.

Vitamin D is a hormone with a pleiotropic role and there is compelling evidence for an epidemiological association between low serum 25OHD levels and human infections such as influenza, HIV, and hepatitis C virus infection (19). The interplay between vitamin D and viral infection is an area of growing interest, and interaction with host and viral factors, immunomodulatory effects, induction of autophagy and apoptosis, and even genetic and epigenetic factors have been reported as antiviral effects of this hormone (20). In this scenario, the SARS-CoV-2 virus pandemic has rapidly spread during winter with extreme virulence through southern European countries such as Italy and Spain. Although there was a considerable variation in the prevalence of vitamin D deficiency across countries, mainly dependent on age and the use of

### Table 3. Main features in COVID-19 patients with or without oral vitamin D supplements at admission

| Variable | COVID-19 N = 197 | COVID-19_D N = 19 | P |
|----------|------------------|------------------|----------------|
| **Clinical and laboratory data** | | | |
| Pneumonia, n (%) | 188 (95.4) | 18 (94.7) | .999 |
| Respiratory rate >22, n (%) | 40 (20.3) | 3 (15.8) | .772 |
| CURB-65 score, median (IQR) | 1 (1, 2) | 1 (1, 2) | .353 |
| SBP < 100 mmHg, n (%) | 5 (2.5) | 0 (0.0) | .999 |
| PaO2/FIO2 ratio, median (IQR) | 444 (428-452) | 444 (432-452) | .524 |
| PaO2/FIO2 ratio < 300, n (%) | 52 (26.4) | 1 (5.3) | .049 |
| Lymphocytes (mm$^3$), median (IQR) | 900 (700-1200) | 900 (500-1400) | .890 |
| Neutrophils (mm$^3$), median (IQR) | 3900 (2900-5600) | 4000 (2200-5100) | .624 |
| Neutrophil/Lymphocyte ratio, median (IQR) | 4.75 (3.00-7.38) | 4.58 (2.81-7.82) | .891 |
| Platelet count (x10$^9$/L), median (IQR) | 167 (138-214) | 168 (142-236) | .478 |
| D-dimer (ng/mL), median (IQR) | 735.5 (254.3-1367.3) | 599 (431-1336) | .731 |
| Ferritin (ng/mL), median (IQR) | 861 (330-1418) | 315 (147.0-743.0) | .012 |
| hs-Troponin I (ng/L), median (IQR) | 6.0 (3.5-125.0) | 7.0 (3.5-17.0) | .979 |
| C-reactive protein (mg/dl), median (IQR) | 5.55 (2.60-11.85) | 7.30 (2.90-15.10) | .73 |
| IL-6 (pg/mL), median (IQR) | 57.6 (21.6-125.0) | 48.8 (13.0-129.8) | .80 |
| **Therapeutic scheme** | | | |
| Hydroxychloroquine, n (%) | 191 (97.0) | 19 (100) | .999 |
| Lopinavir/ritonavir, n (%) | 153 (77.7) | 12 (63.2) | .164 |
| Azithromycin, n (%) | 147 (74.6) | 14 (73.7) | .999 |
| Corticosteroids, n (%) | 47 (23.9) | 5 (26.3) | .783 |
| β-interferon, n (%) | 44 (22.3) | 2 (10.5) | .378 |
| Tocilizumab, n (%) | 63 (32.0) | 1 (5.3) | .015 |
| Anakinra, n (%) | 13 (6.6) | 1 (5.3) | .999 |
| Non-invasive ventilation, n (%) | 13 (6.6) | 2 (10.5) | .627 |
| **Outcome** | | | |
| ICU admission, n (%) | 50 (25.4) | 1 (5.3) | .05 |
| Mechanical ventilation*, n (%) | 43 (86.0) | 1 (100) | .999 |
| Radiological worsening, n (%) | 56 (28.4) | 2 (10.5) | .093 |
| Secondary infection, n (%) | 44 (22.3) | 2 (10.5) | .378 |
| Thrombotic events*, n (%) | 10 (5.1) | 1 (5.3) | .999 |
| Death, n (%) | 20 (10.4) | 2 (10.5) | .999 |
| Composite severity endpoint, n (%) | 59 (29.9) | 3 (15.8) | .193 |
| Length of stay (days), median (IQR) | 12.0 (8.0-16.0) | 8.0 (6.0-14.0) | .107 |

Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; ACEI, angiotensin-converting enzyme inhibitors; ARA2, angiotensin-receptor 2 antagonists; hs, high-sensitivity; GFR, glomerular filtration rate; MDRD, modification of diet in renal disease; 25OHD, 25-hydroxyvitamin D; PTH, parathormone.

*aRefers only to the number of patients admitted to ICU.

*bIncluded pulmonary embolism, deep venous thrombosis, acute coronary syndrome, and cerebrovascular disease.
vitamin D supplements or food fortification, vitamin D deficiency (25OHD levels <20 ng/mL) is found in 40% of European citizens irrespective of age group, ethnic mix, and latitude (18). The population with more severe COVID-19, such as elderly people and patients with comorbidities with the highest case fatality rates (21), are also those with lower serum 25OHD levels according to published data (18). Thus, the Seneca study showed a mean 25OHD concentration of 10.4 ng/mL (26 nmol/L) in elderly subjects aged 70 to 75 years in Spain (22). Recently, Ilie et al. (23) found significant crude associations between serum vitamin D levels and the number of COVID-19 cases and mortality when they analyzed, in some European countries, the mean 25OHD levels reported in some population studies.

Moreover, SARS-CoV-2 downregulates ACE2 expression, the main receptor for the virus to enter human cells, and thereby induces high angiotensin II production leading to myocardial and mainly lung inflammation and ARDS (24). In experimental models, vitamin D deficiency induces chronic RAS activation leading to impaired lung function and overexpression of profibrotic factors (13). The key pathogenic mechanism for SARS-CoV-2 to develop severe complications and lethality is the hyperinflammatory state (“cytokine storm”) that occurs over the first week of the onset of the symptoms. This cytokine storm may lead to severe COVID-19 complications, such as ARDS, myocarditis, and acute heart and renal failure, causing increased mortality, especially in elderly people or in patients with previous cardiovascular comorbidity (25). The intrinsic mechanism of the anti-inflammatory effect of vitamin D remains uncertain, although its role on both, innate and adaptive immunity, has been suggested (26). In this regard, experimental evidence indicates that vitamin D may inhibit IL-6 and tumor necrosis factor-α by attenuating p38 MAP kinase activation in human monocytes/macrophages, Moreover, 1,25OH2D3 promotes the induction of T regulatory cells, thereby inhibiting production of proinflammatory cytokines, including IL-17, IL-21, and γ-interferon (27).

In this scenario, a recent study using 350 000 UK Biobank samples obtained between 2006 and 2010 did not find an association between serum 25OHD concentrations (or vitamin D deficiency, defined as <25 mmol/L; or insufficiency <50 mmol/L) and COVID-19 risk (assessed in 449

---

**Figure 1.** Serum vitamin D levels in hospitalized COVID-19 patients with and without active oral vitamin D supplements and population-based controls, according to gender. Grey bars represent men and white bars represent women.

**Figure 2.** Percentage of COVID-19 cases (excluding those on vitamin D at admission) and controls according to different intervals of serum 25OHD levels.
COVID-19 patients with complete data), after adjusting for potential confounders. Besides, their results did not support that vitamin D might play a role in the reported ethnic variations in COVID-19 incidence (28). Baseline 25OHD levels were obtained a decade ago; information on the severity of COVID-19 was also lacking and the study included all positive tests regardless of clinical outcome. D’Avolio et al. (29) retrospectively analyzed 107 patients who underwent SARS-CoV-2 polymerase chain reaction testing (80 with a negative and only 27 with a positive result) and simultaneous 25OHD measurement, in a Swiss hospital, from March 1 to April 14, 2020. A control cohort that included 1377 patients with serum 25OHD levels obtained in the same period of the year 2019 was also analyzed. The authors found that SARS-CoV-2-infected patients had median 25OHD levels of 11.1 ng/mL, compared with 24.6 ng/mL in SARS-CoV-2-negative subjects and controls.

Our study was carried out in a hospitalized population, and, in this sense, it is worth mentioning that serum 25OHD has been considered as a negative acute-phase reactant, and its values have been reported to be decreased during acute inflammatory diseases (30). Thus, our COVID-19 patients had a high prevalence of vitamin D deficiency, and serum 25OHD levels significantly and negatively correlated with ferritin and D-dimer values, indicating that vitamin D might have a beneficial role on the systemic inflammatory state of this viral disease. Interestingly, 25OHD concentrations in COVID-19 patients on previous hormone supplements were lower than expected, supporting its behavior as a negative acute-phase reactant. Therefore, 25OHD levels should be interpreted with caution in this scenario, although the population at risk for a more severe SARS-CoV-2 infection is probably the same as that at risk for vitamin D deficiency, especially elderly individuals with comorbidities.

We did not find any relationship between serum 25OHD levels and the parameters of COVID-19 severity, such as ICU admission, the need for mechanical ventilation, or mortality, assessed as a combined endpoint or separately. In contrast to other studies (31, 32), we did not find an association between serum 25OHD levels and the severity of the disease. However, it cannot be completely ruled out due to the small number of events and the statistical power of the present study. Nevertheless, we had the opportunity to assess a group of 19 COVID-19 patients who were on oral vitamin D supplements at hospital admission. We observed that they had a slightly less unfavorable outcome than COVID-19 patients who did not take vitamin D supplements, with a significantly more favorable PaO₂/FIO₂.

Figure 3. Correlation between serum 25OHD and inflammatory markers (ferritin, A; D-dimer, B; and C-reactive protein, C).
ratio, lower ferritin levels, and decreased requirements for tocilizumab, and even a trend for lower ICU admissions.

Interestingly enough, 6 out of 19 COVID-19 patients on vitamin D supplements also received chronic corticosteroids or immunosuppressant agents at least during the previous 3 months because of immune-mediated inflammatory diseases (IMIDs) or suprarenal insufficiency. This is an interesting matter of debate since it has been recently suggested that the use of anticytokine and other immunosuppressive therapies is not associated with worse COVID-19 outcomes (33). In this sense, IMID patients on chronic corticosteroids usually received vitamin D supplements as prophylaxis or treatment of bone disease. Furthermore, they are under tight control of their comorbidities, and vitamin D deficiency is more frequently checked and treated than in the general population. Whether the outcome of COVID-19 patients on previous vitamin D might have been influenced by vitamin D status itself or by the presence of an important number of patients with IMIDs on corticosteroids and/or immunosuppressant agents is difficult to determine due to the size of the sample.

COVID-19 hospitalized patients had lower serum corrected calcium levels than the control population. In this regard, Di Filippo et al. (34) conducted a hospital-based retrospective study on 531 COVID-19 patients in Italy. Hypocalcemia, defined as serum ionized calcium level <1.18 mmol/L, was observed in 82% of patients, mainly elderly males. They also found that hypocalcemia was an independent predictor for hospitalization. However, and despite lower calcium and vitamin D levels in our COVID-19 patients, serum parathyroid hormone was higher in controls. This could be related to a lower glomerular filtration rate in the control population, since there is no reason to suspect relative hypoparathyroidism.

Finally, it is worth mentioning that the SARS-CoV-2 pandemic represents a challenging scenario in the management of osteoporosis and fragility fractures. Thus, COVID-19 hospitalized patients are mainly frail, older individuals with comorbidities, who are in many cases exposed to systemic corticosteroids as part of the treatment of the disease and may require prolonged immobilization periods for a complete recovery. Besides, as we observed, they have a high percentage of vitamin D deficiency that may also contribute to a loss of muscle strength and to an increase in the risk of falls. All these factors put these individuals at an increased risk for fragility fractures (35, 36). Under these circumstances, prevention strategies should be implemented. According to our results, vitamin D treatment should be recommended in COVID-19 patients with serum 25OHD deficiency, since this approach might have beneficial effects in both the musculoskeletal and the immune system (36). Our study has several limitations. First of all, those inherent to an observational study that does not permit one to establish whether vitamin D is simply a biomarker of exposure or a biomarker of effect on the disease. Other vitamin D-related parameters such as the free fraction of 25OHD, 1,25 dihydroxyvitamin D, and vitamin D binding protein were not measured. The number of COVID-19 patients who were on oral vitamin D supplements is too small and on different dosages to draw solid conclusions about its role in the clinical outcomes of the disease, although we think that it represents a unique opportunity to preliminary explore the differences between both groups of COVID-19 patients. Furthermore, the study has been conducted in a single Spanish tertiary care hospital, and data may not be generalized to other settings, ethnicities, or countries, especially those with specific policies for vitamin D supplementation or food fortification. The methods to assess serum 25OHD levels in cases and controls were different, although, as stated, we have found a very good correlation between both techniques. Finally, no dietary assessment was carried out, and therefore information on dietary habits is lacking.

In summary, serum 25OHD levels of hospitalized COVID-19 patients are lower than sex-matched population-based controls of similar age. Men with this viral disease represent the group with lower serum vitamin D levels than women. Serum vitamin D levels below 20 ng/mL were detected in 82% of COVID-19 patients, indicating that they represent a population with a higher risk for vitamin D deficiency. In our COVID-19 patients, 25OHD was inversely associated with some inflammatory parameters, such as ferritin and D-dimer. We did not find any relationship between vitamin D concentrations or vitamin deficiency and the severity of the disease, including mortality, although further studies including a large sample size should be done to determine the real impact of vitamin D deficiency on the severity of COVID-19. Probably the best approach should be to identify and treat vitamin D deficiency, especially in high-risk individuals such as elderly people, patients with comorbidities, and nursing home residents, to maintain serum 25OHD levels above 20 ng/mL, and probably with a target between 30 ng/mL and 50 ng/mL. Whether the treatment of vitamin D deficiency will play some role in the prevention of the viral disease or improve the prognosis of patients with COVID-19 remains to be elucidated in large randomized controlled trials, which will be certainly necessary to precisely define the role of vitamin D supplementation in future waves of SARS-CoV-2 infection.

Acknowledgments

**HUMV-COVID group (in alphabetical order):** Cristina Abad, Beatriz Abascal, Mario Agudo, Juan Alonso, Lucía Alonso, Inés Álvarez, Sofia Álvarez, Carlos Amado, Guido Andretta, Carlos...
Armiñanzas, Ana M. Arnaiz, Francisco Arnaiz, Laura Ayarza, Cristina Baldeón, María A. Ballesteros, Eva Barrero, María J. Bartolomé, Lara Belmar, Arancha Bermúdez, Ana Benraza, Carmen Blanco, Teresa Borderas, Marta Boya, Javier Burón, Alejandro Caballero, Marta Caballo, Vanesa Calvo-Rio, Sandra Campos, Violeta Cantero, Santiago Cantoya, Lucía Cañamero, Belén Caramelo, Juan M. Cerezo, Marina Cherchi, José M. Cifrín, María Cobreros, Alicia Cuesta, Sandra de la Roz, María del Barrio, Sara Delgado, Álvaro Díaz, Teresa Díaz de Terán, Juan J. Domínguez, Mathew Domínguez, María J. Domínguez, Carlos Durán, Patricia Escudero, Carmen Fariñas, Marina Fayos, Marlene Feo, Marta Fernández-Sampedro, Sonia Fernández-Jorde, Diego Ferrer, Patricia Fierro, Jimmy Flores, José Ignacio Fortea, María J. García, José D. García, Adrián García, Patricia García, Ana García-Migüelés, Carmen García-Ibarbia, Luis Gibert, Artiz Gil, Alejandro J. Gil, Mónica González, Pablo González, Alejandro González, Paula González-Bores, Sofía González-Lizarbe, Laura Gutiérrez, María C. Gutiérrez del Río, Marina Haro, Rosa Herreras, María S. Holanda, Andrés Insunza, David Iteurbe, Sheila Izquierdo, José M. Lanza, Maite Latorre, Miguel Llano, Susana Llerena, Marta López, Miriam López, Carlos López, Ana López, Sara López-Garcia, María López-Delgado, Iciar Lorda, José L. Lozano, Jorge Madera, Tamara Maestre, Adrián Magarida, Juan Martín, Marta Martín-Millán, Amaya Martínez, David Martínez, Gonzalo Martín Martínez de las Cuevas, Joel Mazariegos, Iván Mazón, Maite Menéndez, Eduardo Miñámbres, Víctor Mora, Pablo Munigua, José J. Napal, Yigio Navarro, Sara Nieto, Tomás Obeso, Aitor Odrozola, Félix Ortiz, Marta Ortíz, Fernando Ortíz, Elsa Ots, Javier Pardo, Juan Parra, Raúl Parra, Ana C. Pascual, Yhivian Peñasco, José L. Pérez-Canga, Jesús Pérez del Molino, Nuria Puente, Leandro Reguero, Adriana Reyes, José A. Riancho, Eloy Rodríguez, Bryan Rodríguez, Juan C. Rodríguez-Borregán, Felix Romay, Cristina Ruiz, Luis J. Ruiz, Ana Ruiz, Jaime Salas, Zaida Salmón, Borja Sampedro, Juncal Sánchez-Arguiano, Laura Sánchez-Togneri, Juan Sánchez-Ceña, María J. Sánchez-Aranguez, Patricio Seabrook, David Serrano, Marina Serrano, Nicolás Sierrasumaga, Marta Sotelo, Borja Suberviola, Beatriz Tapia, Guillermo Tejón, Sandra Tello, Sonia Trabanco, Idoia Valduvieco, Carmen Valero, María T. Valiente, Lucrecia Yáñez, Zoilo Yusta, Miguel A. Zabaleta.

Financial Support: The Camargo Cohort Study was supported by grants from the Instituto de Salud Carlos III (PI18/00762), Ministerio de Economía y Competitividad, Spain, which included FEDER funds from the EU.

Author Contributions: J.L.H., P.M.C., and V.M.T. designed the research and analyzed the data. D.N., M.E.A., and M.A.H. collected the data; M.L.H. and M.G.U. performed the laboratory analyses. J.L.H. and V.M.T. wrote the manuscript; P.M.C., M.L.H., J.M.O., J.R.B., M.G.C., M.A.H., and J.C. critically revised the manuscript. All authors discussed the results and contributed to the final paper.

Additional Information

Correspondence and Reprint Requests: José Luis Hernández, Department of Internal Medicine, Hospital Universitario Marqués de Valdecilla, University of Cantabria, Avda. Valdecilla s/n. 39008, Santander, Spain. E-mail: joseluis.hernandez@scsalud.es.

Disclosure Summary: Dr. Hernández reports research grants form Amgen and fees for lectures or speaker bureau from Amgen, MSD, and Bayer, outside the submitted work. Dr. Crespo reports grants and research support from Gilead Sciences, AbbVie, MSD and Intercept Pharmaceuticals (all outside the submitted work) and speaker for Gilead Sciences and AbbVie. Drs. Martínez-Taboada, Nan, Fernández-Ayala, Hernández-Hernández, López-Hoyos, García-Zunetta, Muñoz-Cacho, Olmos, Cubillán, and Gutiérrez-Cuadra, have nothing to disclose.

Data Availability: Some or all datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

References

1. González-Molero I, Morcillo S, Valdés S, et al. Vitamin D deficiency in Spain: a population-based cohort study. *Euro J Clin Nutr*. 2011;65(3):321-328.

2. Khafie MA, Rahim F. Cross-country comparison of case fatality rates of COVID-19/SARS-COV-2. *Osong Public Health Res Perspect*. 2020;11(2):74-80.

3. Alvarez-Rodriguez L, Lopez-Hoyos M, Garcia-Zunetta M, Amado JA, Cacho PM, Martínez-Taboada VM. Age and low levels of circulating vitamin D are associated with impaired innate immune function. *J Leukoc Biol*. 2012;91(5):829-838.

4. Gois PHF, Ferreira D, Olenksi S, et al. Vitamin D and infectious diseases: simple bystander or contributing factor? *Nutrients*. 2017;9(7):651.

5. Watkins RR, Lemonovich TI, Salata RA. An update on the association of vitamin D deficiency with common infectious diseases. *Can J Physiol Pharmacol*. 2015;93(3):363-368.

6. Ananthakrishnan AN, Cheng SC, Cai T, et al. Association between reduced plasma 25-hydroxy vitamin D and increased risk of cancer in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol*. 2014;12(5):821-827.

7. Schwalfenberg G. Vitamin D and diabetes: improvement of glycemic control with vitamin D3 repletion. *Can Fam Physician*. 2008;54(6):864-866.

8. Joukar F, Naghipour M, Hassanipour S, et al. Association of vitamin D deficiency with common infectious diseases. *Clin Gastroenterol Hepatol*. 2017;15(9):1054-1062.

9. Watkin J, Roughley RJ, Saifan A, et al. Understanding novel COVID-19: its impact on organ failure and risk assessment for diabetic and cancer patients. *Cytokine Growth Factor Rev*. 2020;53:43-52.

10. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-1062.

11. Dariya B, Nagaraju GP. Understanding novel COVID-19: its impact on organ failure and risk assessment for diabetic and cancer patients. *Cytokine Growth Factor Rev*. 2020;53:43-52.

12. Zhang Y, Leung DY, Richers BN, et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. *J Immunol*. 2012;188(5):2127-2135.

13. Shi Y, Liu T, Yao L, et al. Chronic vitamin D deficiency induces lung fibrosis through activation of the renin-angiotensin system. *Sci Rep*. 2017;7(1):3312.

14. Hernández JL, Olmos JM, Patience E, et al. Metabolic syndrome and bone metabolism: the Camargo Cohort study. *Menopause*. 2010;17(5):955-961.
15. Olmos JM, Hernández JL, Pariente E, Martínez J, González-Macías J. Serum 25-Hydroxyvitamin D in obese Spanish adults: the Camargo Cohort Study. Obes Surg. 2018;28(12):3862-3871.

16. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67.

17. Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias. Recomendaciones éticas para la toma de decisiones en la situación excepcional de crisis por pandemia COVID-19 en las unidades de cuidados intensivos (SEMICYUC). ProMED-mail website. https://semicyuc.org/wp-content/uploads/2020/03/%C3%89tica_SEMICYUC-COVID-19.pdf. Accessed June 1, 2020.

18. Lips P, Cashman KD, Lamberg-Allardt C, et al. Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. Eur J Endocrinol. 2019;180(4):P23-P54.

19. Hewison M. An update on vitamin D and human immunity. Clin Endocrinol (Oxf). 2012;76(3):315-325.

20. Grant WB, Lahore H, McDonnell SL, et al. Evidence that Vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020;12(4):988.

21. Guan WJ, Ni ZY, Hu Y, et al.; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.

22. van der Wielen RP, Löwik MR, van den Berg H, et al. Serum vitamin D concentrations among elderly people in Europe. Lancet. 1995;346(8969):207-210.

23. Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin Exp Res. 2020;32(7):1195-1198.

24. Zhu H, Rhee JW, Cheng P, et al. Cardiovascular complications in patients with COVID-19: consequences of viral toxicities and host immune response. Curr Cardiol Rep. 2020;22(5):32.

25. Tay MZ, Poh CM, Réenia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-374.

26. Tramontana F, Napoli N, El-Hajj Fuleihan G, Strollo R. The D-side of COVID-19: musculoskeletal benefits of vitamin D and beyond. Endocrine. 2020;69(2):237-240.

27. Jeffery LE, Burke F, Mura M, et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol. 2009;183(9):5458-5467.

28. Hastic CE, Mackay DE, Ho F, et al. Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes Metab Syndr. 2020;14(4):561-565.

29. D’Avolio A, Avataneo V, Manca A, et al. 25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2. Nutrients. 2020;12(5):1359.

30. Waldron JL, Ashby HL, Corones MP, et al. Vitamin D: a negative acute phase reactant. J Clin Pathol. 2013;66(7):620-622.

31. Baktash V, Hosack T, Patel N, et al. Vitamin D status and outcomes for hospitalised older patients with COVID-19. [Published online ahead of print August 27, 2020]. Postgrad Med J. 2020. Doi:10.1136/postgradmedj-2020-138712.

32. Radujkovic A, Hippchen T, Tiwari-Heckler S, Dreher S, Boxberger M, Merle U. Vitamin D deficiency and outcome of COVID-19 patients. Nutrients. 2020;12(9):E2757.

33. Haberman R, Axelrad J, Chen A, et al. Covid-19 in immune-mediated inflammatory diseases—case series from New York. N Engl J Med. 2020;383(1):85-88.

34. Di Filippo L, Formenti AM, Rovere-Querini P, et al. Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19. Endocrine. 2020;68(3):475-478.

35. Yu EW, Tsourdi E, Clarke BL, Bauer DC, Drake MT. Osteoporosis management in the era of COVID-19. J Bone Miner Res. 2020;35(6):1009-1013.

36. Napoli N, Elderkin AL, Kiel DP, Khosla S. Managing fragility fractures during the COVID-19 pandemic. Nat Rev Endocrinol. 2020;16(9):467-468.